BD agreed to invest $19 billion in US manufacturing in return for exemption from any future Section 232 tariffs on its products. The partnership with the Trump administration was announced on October 6. Of the total, $3 billion goes to expanding strategic production sites, and the tariff exemption holds only if BD meets milestones that have not been disclosed.
BD expects to add roughly 5 billion essential medical consumables a year of US output, lifting its domestically supplied share of essential medical technology to about 80 percent. Named sites include Columbus and Broken Bow, Nebraska; Canaan, Connecticut; Anasco, Puerto Rico; Sandy, Utah; El Paso, Texas; Covington, Georgia; and Sumter, South Carolina. BD also agreed to make every needle it sells in the US with American steel. It has not quantified the financial effect, since the rates and covered products are not final.
The Section 232 inquiry into medtech opened in September 2025 and no device-specific tariffs have been announced. A company with $19 billion to commit can settle its exposure before the rates exist. A startup whose contract manufacturer sits in Asia has no equivalent lever, and will learn its rate when the rest of the sector does.